Pharmacokinetic/Pharmacodynamic and Time-to-Event Models of Ribavirin-Induced Anaemia in Chronic Hepatitis C-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pharmacokinetic/Pharmacodynamic and Time-to-Event Models of Ribavirin-Induced Anaemia in Chronic Hepatitis C

Published:2005 Issue:4 Volume:44 Page:417-428
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clinical Pharmacokinetics

Author:

Tod Michel,Farcy-Afif Muriel,Stocco Jeanick,Boyer Nathalie,Bouton Val??rie,Sin??gre Martine,Marcellin Patrick

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Reference20 articles.

1. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

2. Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C

3. Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C

4. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: A meta-analysis of controlled and uncontrolled trials

5. Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Finding the right hazard function for time‐to‐event modeling: A tutorial and Shiny application;CPT: Pharmacometrics & Systems Pharmacology;2022-04-28

2. Emergent Drug and Nutrition Interactions in COVID-19: A Comprehensive Narrative Review;Nutrients;2021-05-04

3. COVID-19 outbreak: Challenges in pharmacotherapy based on pharmacokinetic and pharmacodynamic aspects of drug therapy in patients with moderate to severe infection;Heart & Lung;2020-11

4. Dose-Response-Time Data Analysis: An Underexploited Trinity;Pharmacological Reviews;2018-12-26

5. Time-to-Event Modeling of Left- or Right-Censored Toxicity Data in Nonclinical Drug Toxicology;Toxicological Sciences;2018-05-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3